Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system

被引：41

作者：

Ketkar, Harshada ^{[1
]}

Yang, Long ^{[1
]}

Wormser, Gary P. ^{[2
]}

Wang, Penghua ^{[1
]}

机构：

[1] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA

[2] New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2019年 / 95卷 / 01期

基金：

美国国家卫生研究院;

关键词：

Zika virus; Ivermectin; Mouse model; Treatment; INHIBITOR; REPLICATION;

D O I：

10.1016/j.diagmicrobio.2019.03.012

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The antihelminthic drug ivermectin has been demonstrated to have antiviral activity against the Zika virus and other arboviruses in in vitro studies. The effectiveness of ivermectin for Zika virus infection, however, has never been studied in an animal model. In this study, ivermectin was found to be ineffective for prevention of a lethal infection with the Senegal strain of Zika virus in Ifnar1 knockout mice. In view of several study limitations, evaluation of ivermectin's anti-Zika virus activity in other animal models and against other Zika virus strains would be desirable. (C) 2019 Elsevier Inc. All rights reserved.

引用

页码：38 / 40

页数：3

共 15 条

[1] Therapeutic Approaches for Zika Virus Infection of the Nervous System [J].

Abrams, Rachel P. M. ;

Solis, Jamie ;

Nath, Avindra .

NEUROTHERAPEUTICS, 2017, 14 (04) :1027-1048

[2]

[Anonymous], 2010, VANC PACK INS

[3] A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection [J].

Barrows, Nicholas J. ;

Campos, Rafael K. ;

Powell, Steven T. ;

Prasanth, K. Reddisiva ;

Schott-Lerner, Geraldine ;

Soto-Acosta, Ruben ;

Galarza-Munoz, Gaddiel ;

McGrath, Erica L. ;

Urrabaz-Garza, Rheanna ;

Gao, Junling ;

Wu, Ping ;

Menon, Ramkumar ;

Saade, George ;

Fernandez-Salas, Ildefonso ;

Rossi, Shannan L. ;

Vasilakis, Nikos ;

Routh, Andrew ;

Bradrick, Shelton S. ;

Garcia-Blanco, Mariano A. .

CELL HOST & MICROBE, 2016, 20 (02) :259-270

[4]

Chiu S.-H. L., 1989, IVERMECTIN ABAMECTIN, P131, DOI DOI 10.1007/978-1-4612-3626-9

[5]

Conole J, 2003, CONTEMP TOP LAB ANIM, V42, P42

[6] Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin [J].

Croci, Romina ;

Bottaro, Elisabetta ;

Chan, Kitti Wing Ki ;

Watanabe, Satoru ;

Pezzullo, Margherita ;

Mastrangelo, Eloise ;

Nastruzzi, Claudio .

INTERNATIONAL JOURNAL OF BIOMATERIALS, 2016, 2016

[7] Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations [J].

Crump, Andy .

JOURNAL OF ANTIBIOTICS, 2017, 70 (05) :495-505

[8] Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects [J].

Guzzo, CA ;

Furtek, CI ;

Porras, AG ;

Chen, C ;

Tipping, R ;

Clineschmidt, CM ;

Sciberras, DG ;

Hsieh, JYK ;

Lasseter, KC .

JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (10) :1122-1133

[9] A Mouse Model of Zika Virus Pathogenesis [J].

Lazear, Helen M. ;

Govero, Jennifer ;

Smith, Amber M. ;

Platt, Derek J. ;

Fernandez, Estefania ;

Miner, Jonathan J. ;

Diamond, Michael S. .

CELL HOST & MICROBE, 2016, 19 (05) :720-730

[10] Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug [J].

Mastrangelo, Eloise ;

Pezzullo, Margherita ;

De Burghgraeve, Tine ;

Kaptein, Suzanne ;

Pastorino, Boris ;

Dallmeier, Kai ;

de Lamballerie, Xavier ;

Neyts, Johan ;

Hanson, Alicia M. ;

Frick, David N. ;

Bolognesi, Martino ;

Milani, Mario .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (08) :1884-1894

← 1 2 →